Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

M Reck; S Popat; C Grohe; J Corral; S Novello; M Gottfried; W Brueckl; D Radonjic; R Kaiser; J Heymach

doi:10.1016/j.lungcan.2023.03.009

Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

M Reck, S Popat, C Grohe, J Corral, S Novello, M Gottfried, W Brueckl (Co-author), D Radonjic, R Kaiser, J Heymach

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Review article › peer-review

12 Citations (Web of Science)

Original language	English
Pages (from-to)	107173
Journal	LUNG CANCER
Volume	179
DOIs	https://doi.org/10.1016/j.lungcan.2023.03.009
Publication status	Published - 2023

Keywords

CELL LUNG-CANCER
RAMUCIRUMAB PLUS ATEZOLIZUMAB
TRIPLE ANGIOKINASE INHIBITOR
IMMUNE CHECKPOINT INHIBITORS
SPECIFIED FINAL ANALYSIS
RANDOMIZED PHASE-III
WILD-TYPE EGFR
OPEN-LABEL
PATIENTS PTS
DOCETAXEL

Access to Document

10.1016/j.lungcan.2023.03.009

Cite this

@article{7e49917bbdf74615b8db6af6e2a6ead0,

title = "Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives",

keywords = "CELL LUNG-CANCER, RAMUCIRUMAB PLUS ATEZOLIZUMAB, TRIPLE ANGIOKINASE INHIBITOR, IMMUNE CHECKPOINT INHIBITORS, SPECIFIED FINAL ANALYSIS, RANDOMIZED PHASE-III, WILD-TYPE EGFR, OPEN-LABEL, PATIENTS PTS, DOCETAXEL",

author = "M Reck and S Popat and C Grohe and J Corral and S Novello and M Gottfried and W Brueckl and D Radonjic and R Kaiser and J Heymach",

note = "Brueck: Department of Respiratory Medicine, Allergology and Sleep Medicine, Nuremberg Lung Cancer Center, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany",

year = "2023",

doi = "10.1016/j.lungcan.2023.03.009",

language = "English",

volume = "179",

pages = "107173",

journal = "LUNG CANCER ",

issn = "0169-5002",

publisher = "Elsevier ",

}

TY - JOUR

T1 - Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

AU - Reck, M

AU - Popat, S

AU - Grohe, C

AU - Corral, J

AU - Novello, S

AU - Gottfried, M

AU - Brueckl, W

AU - Radonjic, D

AU - Kaiser, R

AU - Heymach, J

N1 - Brueck: Department of Respiratory Medicine, Allergology and Sleep Medicine, Nuremberg Lung Cancer Center, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany

PY - 2023

Y1 - 2023

KW - CELL LUNG-CANCER

KW - RAMUCIRUMAB PLUS ATEZOLIZUMAB

KW - TRIPLE ANGIOKINASE INHIBITOR

KW - IMMUNE CHECKPOINT INHIBITORS

KW - SPECIFIED FINAL ANALYSIS

KW - RANDOMIZED PHASE-III

KW - WILD-TYPE EGFR

KW - OPEN-LABEL

KW - PATIENTS PTS

KW - DOCETAXEL

U2 - 10.1016/j.lungcan.2023.03.009

DO - 10.1016/j.lungcan.2023.03.009

M3 - Review article

C2 - 36940614

SN - 0169-5002

VL - 179

SP - 107173

JO - LUNG CANCER

JF - LUNG CANCER

ER -